{"organizations": [], "uuid": "e58d33deeaa3226cc0c6f1ac703c91f12e579bf1", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 2, "shares": 2, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180518.html", "section_title": "Archive News &amp; Video for Friday, 18 May 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-fda-issues-alert-on-use-of-keytrud/brief-fda-issues-alert-on-use-of-keytruda-tecentriq-for-patients-with-urothelial-cancer-have-low-expression-of-pd-l1-idUSFWN1SP0UY", "country": "US", "domain_rank": 408, "title": "BRIEF-FDA Issues Alert On Use Of Keytruda/Tecentriq For Patients With Urothelial Cancer, Have Low Expression Of PD-L1", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 1.0, "site_type": "news", "published": "2018-05-19T00:21:00.000+03:00", "replies_count": 0, "uuid": "e58d33deeaa3226cc0c6f1ac703c91f12e579bf1"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-fda-issues-alert-on-use-of-keytrud/brief-fda-issues-alert-on-use-of-keytruda-tecentriq-for-patients-with-urothelial-cancer-have-low-expression-of-pd-l1-idUSFWN1SP0UY", "ord_in_thread": 0, "title": "BRIEF-FDA Issues Alert On Use Of Keytruda/Tecentriq For Patients With Urothelial Cancer, Have Low Expression Of PD-L1", "locations": [], "entities": {"persons": [{"name": "merck", "sentiment": "none"}], "locations": [{"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "fda", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "genentech", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 18 (Reuters) - FDA:\n* U.S. FDA - ISSUES ALERT ABOUT DECREASED SURVIVAL ASSOCIATED WITH THE USE OF KEYTRUDA (PEMBROLIZUMAB) OR TECENTRIQ (ATEZOLIZUMAB)\n* U.S. FDA SAYS THERE WAS NO CHANGE IN THE ADVERSE EVENT PROFILE OF KEYTRUDA OR TECENTRIQ\n* FDA - MERCK, GENENTECH HAVE STOPPED ENROLLING PATIENTS WHOSE TUMORS HAVE PD-L1 LOW STATUS TO KEYTRUDA/TECENTRIQ MONOTHERAPY ARMS PER DMCSâ€™ RECOMMENDATIONS\n* U.S. FDA SAYS MONOTHERAPY ARMS REMAIN OPEN ONLY TO PATIENTS WHOSE TUMORS HAVE PD-L1 HIGH STATUS\n* U.S. FDA - COMBINATION ARMS AND THE CHEMOTHERAPY ARMS OF BOTH STUDIES ALSO REMAIN OPEN\n* FDA - ISSUED ALERT ON KEYTRUDA/TECENTRIQ AS MONOTHERAPY FOR PATIENTS WITH UROTHELIAL CANCER WHO HAVE NOT RECEIVED PRIOR THERAPY, HAVE LOW EXPRESSION OF PD-L1 Source text : ( bit.ly/2k9egH8 ) Further company coverage:\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "http://bit.ly/2k9egH8", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-05-19T00:21:00.000+03:00", "crawled": "2018-05-19T15:20:21.003+03:00", "highlightTitle": ""}